Policy / Regulatory

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
NHC (NHFPC)NMPA

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
China's NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030
NHC (NHFPC)

China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030

NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs
NHSA (prev. SMIA)

NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
NHC (NHFPC)

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030

AstraZeneca's ALXN1850 (Efzimfotase Alfa) Selected for China's Rare Disease Care Plan
AstraZenecaAZ

AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan

Show More